<?xml version="1.0"?>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Incidence of infectious morbidity events after second-line antiretroviral therapy initiation in HIV-infected adults in Yaound&#xE9;, Cameroon</dc:title>
  <dc:creator>Galy, A.</dc:creator>
  <dc:creator>Ciaffi, L.</dc:creator>
  <dc:creator>Le Moing, V.</dc:creator>
  <dc:creator>/Eymard-Duvernay, Sabrina</dc:creator>
  <dc:creator>Abessolo, H.</dc:creator>
  <dc:creator>Toby, R.</dc:creator>
  <dc:creator>Ayangma, L.</dc:creator>
  <dc:creator>Le Gac, S.</dc:creator>
  <dc:creator>Mpoudi-Etame, M.</dc:creator>
  <dc:creator>Koulla-Shiro, S.</dc:creator>
  <dc:creator>Delaporte, Eric</dc:creator>
  <dc:creator>/Cournil, Amandine</dc:creator>
  <dc:description>Background: Since antiretroviral therapy (ART), HIV-infected individuals experience mainly non-AIDS-related conditions, among which infectious events are prominent. We aimed to estimate incidence and describe overall spectrum of infectious events, including all grade events, among HIV-1-infected adults failing first-line ART in Yaounde, Cameroon. Methods: All patients from Cameroon enrolled in the second-line ART 2LADY trial (ANRS12169) were included in this secondary analysis. Medical files were reviewed with predefined criteria for diagnosis assessment. Incidence rates (IR) were estimated per 100 person-years (% PY). Results: A total of 302 adult patients contributing 840 PY experienced 596 infectious events (IR 71% PY). Only 29 (5%) events were graded as severe. Most frequent infections were upper respiratory tract infections (15% PY), diarrhoea (9% PY) and malaria (9% PY). A total of 369 (62%) infections occurred during the first year (IR 130% PY) followed by a persistent lower incidence during the following 3 years. Higher IR were observed in patients with CD4(+) T-cell count &lt; 200 cells/mm(3) for all infectious events except for mycobacterial and parasitic infections. IR of viral, bacterial and parasitic infectious events were lower in case of co-trimoxazole use in patients with CD4(+) T-cell count &lt; 200 cells/mm(3). Conclusions: Infectious events are common and mainly occur during the first year after treatment initiation. Second-line ART initiation had a positive impact on the entire spectrum of infectious morbidity.</dc:description>
  <dc:date>2016</dc:date>
  <dc:type>text</dc:type>
  <dc:identifier>https://www.documentation.ird.fr/hor/fdi:010081630</dc:identifier>
  <dc:identifier>fdi:010081630</dc:identifier>
  <dc:identifier>Galy A., Ciaffi L., Le Moing V., Eymard-Duvernay Sabrina, Abessolo H., Toby R., Ayangma L., Le Gac S., Mpoudi-Etame M., Koulla-Shiro S., Delaporte Eric, Cournil Amandine. Incidence of infectious morbidity events after second-line antiretroviral therapy initiation in HIV-infected adults in Yaound&#xE9;, Cameroon. 2016, 21 (6), 547-552</dc:identifier>
  <dc:language>EN</dc:language>
  <dc:coverage>CAMEROUN</dc:coverage>
  <dc:coverage>YAOUNDE</dc:coverage>
</oai_dc:dc>
